These mutations result in increased production of FGF23, leading to chronic hypophosphatemia and reduced synthesis of active vitamin D.2The global prevalence of XLH is estimated to range from 1.4 to 4.8 per 100 000 individuals.3 Here, FGF23 is linked to X-linked hypophosphatemia.